SG10202001042PA - Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM) - Google Patents
Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM)Info
- Publication number
- SG10202001042PA SG10202001042PA SG10202001042PA SG10202001042PA SG10202001042PA SG 10202001042P A SG10202001042P A SG 10202001042PA SG 10202001042P A SG10202001042P A SG 10202001042PA SG 10202001042P A SG10202001042P A SG 10202001042PA SG 10202001042P A SG10202001042P A SG 10202001042PA
- Authority
- SG
- Singapore
- Prior art keywords
- igm
- plasma
- composition
- infectious diseases
- treating infectious
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1722—Plasma globulins, lactoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562201910P | 2015-08-06 | 2015-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202001042PA true SG10202001042PA (en) | 2020-03-30 |
Family
ID=56507435
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201606213SA SG10201606213SA (en) | 2015-08-06 | 2016-07-27 | Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM) |
| SG10202001042PA SG10202001042PA (en) | 2015-08-06 | 2016-07-27 | Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201606213SA SG10201606213SA (en) | 2015-08-06 | 2016-07-27 | Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM) |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10570194B2 (en) |
| EP (1) | EP3135688A3 (en) |
| JP (1) | JP6711719B2 (en) |
| KR (1) | KR20170017802A (en) |
| CN (1) | CN106421779A (en) |
| AR (1) | AR105595A1 (en) |
| AU (1) | AU2016208312B2 (en) |
| BR (1) | BR102016017684A2 (en) |
| CA (1) | CA2937193C (en) |
| CL (1) | CL2016001976A1 (en) |
| IL (1) | IL247010B (en) |
| MX (1) | MX2016009887A (en) |
| RU (1) | RU2731108C2 (en) |
| SG (2) | SG10201606213SA (en) |
| TW (1) | TWI720999B (en) |
| UY (1) | UY36815A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10570194B2 (en) * | 2015-08-06 | 2020-02-25 | Grifols Worldwide Operations Limited | Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM) |
| CA3119238A1 (en) * | 2018-11-30 | 2020-06-04 | Csl Behring Ag | Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin |
| JP2023527864A (en) * | 2020-06-03 | 2023-06-30 | グリフォルス・ワールドワイド・オペレーションズ・リミテッド | Hyperimmune IGG and/or IGM compositions and methods for their preparation and methods for obtaining hyperimmune human plasma from donors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2691708B2 (en) | 1984-09-26 | 1997-12-17 | 住友製薬株式会社 | Human monoclonal antibody and method for producing the same |
| GB8426464D0 (en) * | 1984-10-19 | 1984-11-28 | Technology Licence Co Ltd | Monoclonal antibodies |
| US4918163A (en) * | 1985-09-27 | 1990-04-17 | Pfizer Inc. | Monoclonal antibodies specific for lipid-A determinants of gram negative bacteria |
| EP0303088B1 (en) * | 1987-08-10 | 1992-11-11 | Miles Inc. | Purified igm |
| IL90281A (en) * | 1988-06-06 | 1994-10-07 | Miles Inc | Composition consisting of antibodies of the igm type |
| DE3927111C3 (en) * | 1989-08-17 | 1994-09-01 | Biotest Pharma Gmbh | Process for the preparation of unmodified intravenous IgM and / or IgA-containing immunoglobulin preparations |
| US5240909B1 (en) * | 1990-03-14 | 1998-01-20 | Dietrich Nitsche | Use of lactoferrin for treatment of toxic effects of endotoxins |
| US7473423B2 (en) * | 1994-04-29 | 2009-01-06 | Mayo Foundation For Medical Education And Research | Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| US5886154A (en) | 1997-06-20 | 1999-03-23 | Lebing; Wytold R. | Chromatographic method for high yield purification and viral inactivation of antibodies |
| EP1779849A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of septic shock |
| US7794721B2 (en) | 2006-12-13 | 2010-09-14 | Simon Michael R | Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith |
| US8021645B2 (en) * | 2006-12-13 | 2011-09-20 | Simon Michael R | Synthesis of human secretory IgA and IgM and the formation of a medicament therefrom |
| GB0717864D0 (en) | 2007-09-13 | 2007-10-24 | Peptcell Ltd | Peptide sequences and compositions |
| AU2009246510B2 (en) | 2008-05-12 | 2014-02-13 | Strox Biopharmaceuticals, Llc | Staphylococcus aureus-specific antibody preparations |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| EP2916876B1 (en) | 2012-11-06 | 2021-10-20 | Imbed Biosciences, Inc. | Methods and compositions for wound healing |
| US10570194B2 (en) * | 2015-08-06 | 2020-02-25 | Grifols Worldwide Operations Limited | Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin M (IgM) |
| US9913903B2 (en) * | 2015-08-06 | 2018-03-13 | Grifols Worldwide Operations Limited | Method for the treatment or prevention of infection-related immune conditions using a composition comprising IgM |
-
2016
- 2016-05-17 US US15/156,562 patent/US10570194B2/en active Active
- 2016-07-20 EP EP16180425.7A patent/EP3135688A3/en not_active Ceased
- 2016-07-25 CA CA2937193A patent/CA2937193C/en active Active
- 2016-07-25 UY UY0001036815A patent/UY36815A/en not_active Application Discontinuation
- 2016-07-26 JP JP2016146098A patent/JP6711719B2/en active Active
- 2016-07-27 SG SG10201606213SA patent/SG10201606213SA/en unknown
- 2016-07-27 SG SG10202001042PA patent/SG10202001042PA/en unknown
- 2016-07-27 AU AU2016208312A patent/AU2016208312B2/en active Active
- 2016-07-28 IL IL247010A patent/IL247010B/en active IP Right Grant
- 2016-07-28 MX MX2016009887A patent/MX2016009887A/en unknown
- 2016-07-28 RU RU2016131195A patent/RU2731108C2/en active
- 2016-07-29 BR BR102016017684A patent/BR102016017684A2/en active Search and Examination
- 2016-07-29 CN CN201610609665.1A patent/CN106421779A/en active Pending
- 2016-08-01 TW TW105124305A patent/TWI720999B/en active
- 2016-08-04 KR KR1020160099701A patent/KR20170017802A/en not_active Application Discontinuation
- 2016-08-04 AR ARP160102381A patent/AR105595A1/en unknown
- 2016-08-05 CL CL2016001976A patent/CL2016001976A1/en unknown
-
2020
- 2020-01-17 US US16/745,563 patent/US11208471B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6711719B2 (en) | 2020-06-17 |
| RU2016131195A (en) | 2018-02-01 |
| US11208471B2 (en) | 2021-12-28 |
| UY36815A (en) | 2016-09-30 |
| CN106421779A (en) | 2017-02-22 |
| US20170037115A1 (en) | 2017-02-09 |
| US20200223908A1 (en) | 2020-07-16 |
| AU2016208312B2 (en) | 2022-04-14 |
| RU2731108C2 (en) | 2020-08-28 |
| SG10201606213SA (en) | 2017-03-30 |
| KR20170017802A (en) | 2017-02-15 |
| IL247010A0 (en) | 2016-12-29 |
| EP3135688A3 (en) | 2017-05-17 |
| AU2016208312A1 (en) | 2017-02-23 |
| US10570194B2 (en) | 2020-02-25 |
| IL247010B (en) | 2021-05-31 |
| TWI720999B (en) | 2021-03-11 |
| CA2937193C (en) | 2024-01-30 |
| BR102016017684A2 (en) | 2017-02-14 |
| EP3135688A2 (en) | 2017-03-01 |
| MX2016009887A (en) | 2017-02-06 |
| JP2017036264A (en) | 2017-02-16 |
| CL2016001976A1 (en) | 2017-03-17 |
| AR105595A1 (en) | 2017-10-18 |
| TW201705985A (en) | 2017-02-16 |
| CA2937193A1 (en) | 2017-02-06 |
| RU2016131195A3 (en) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3317336T3 (en) | Method for purifying contaminated polypropylene | |
| HK1251588A1 (en) | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases | |
| PL3317335T3 (en) | Method for purifying contaminated polymers | |
| IL282881A (en) | Methods for treating hepatitis b infection | |
| PL3317334T3 (en) | Method for purifying contaminated polymers | |
| EP3118210A4 (en) | Method for purifying immunoglobulin | |
| PT3303567T (en) | Method for sterilising a platelet lysate | |
| HK1255871A1 (en) | Cerdulatinib for treating myeloma | |
| EP3118209A4 (en) | Method for purifying immunoglobulin | |
| EP3305800C0 (en) | Preparation method of plasma-derived hepatitis b human immunoglobulin agent | |
| ZA201708386B (en) | Treatment for multiple myeloma (mm) | |
| IL247010B (en) | Method for treating infectious diseases using a composition comprising plasma-derived immunoglobulin m (igm) | |
| GB201806736D0 (en) | Method for virus purification | |
| RS62420B1 (en) | Method for preventing infection by plant virus | |
| SG11201805098XA (en) | Alcoholic disinfectant for virus control | |
| GB201819172D0 (en) | Means for treating sexually-transmitted infectious diseases | |
| AP2016009014A0 (en) | Method for treating hiv infection | |
| HUP1500053A1 (en) | Immunoglobulin purification using pre-cleaning steps |